HansBiomed Corporation reported earnings results for the second quarter and six months ended March 31, 2023. For the second quarter, the company reported sales was KRW 20,482.94 million compared to KRW 17,165.37 million a year ago. Net loss was KRW 9,744.1 million compared to net income of KRW 3,375.9 million a year ago. Basic loss per share from continuing operations was KRW 964 compared to basic earnings per share from continuing operations of KRW 341 a year ago. Diluted loss per share from continuing operations was KRW 964 compared to diluted earnings per share from continuing operations of KRW 25 a year ago. Basic loss per share was KRW 964 compared to basic earnings per share of KRW 341 a year ago.
For the six months, sales was KRW 40,554.05 million compared to KRW 34,704.51 million a year ago. Net loss was KRW 14,117.01 million compared to net income of KRW 1,998.25 million a year ago. Basic loss per share from continuing operations was KRW 1,433 compared to basic earnings per share from continuing operations of KRW 201 a year ago. Diluted loss per share from continuing operations was KRW 1,433 compared to KRW 91 a year ago. Basic loss per share was KRW 1,433 compared to basic earnings per share of KRW 201 a year ago.